Month: March 2025

Pactiv Evergreen Inc. Announces Receipt of All Required Regulatory Approvals for Planned Acquisition by Novolex

Written by Customer Service on March 28, 2025. Posted in Mergers And Acquisitions.

LAKE FOREST, Ill., March 28, 2025 (GLOBE NEWSWIRE) — Pactiv Evergreen Inc. (“Pactiv Evergreen” or the “Company”) (NASDAQ: PTVE) today announced that all required regulatory approvals have been received in connection with the Company’s previously announced definitive agreement to be acquired by Novolex® for $18.00 per share in cash. As a result, the transaction is now expected to close on April 1, 2025, subject to satisfaction of other customary closing conditions. Upon the completion of the transaction, Pactiv Evergreen will become a privately held company, and its common stock will no longer be listed on Nasdaq. Goldman Sachs & Co. LLC and Lazard Frères & Co. LLC are acting as financial advisors and Paul Hastings LLP is acting as legal advisor to Pactiv Evergreen. About Pactiv Evergreen Pactiv Evergreen is a leading...

Entera Bio Announces Full Year 2024 Financial Results and Provides Business Updates

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

JERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business achievements for the year ended December 31, 2024. “2024 was a truly transformational year for Entera. We delivered key data read-outs and advanced each of our oral peptide PTH(1-34), GLP1/Glucagon and GLP2 tablet programs, significantly increased our stockholder value, and efficiently strengthened our balance sheet. To our core team with whom I started this journey in late 2022 as a board member, and to our rapidly expanding ecosystem of premier global advisors, I thank you for your commitment and dedication. To our existing and new shareholders, we are grateful for your belief and support of our thesis. To our collaborators,...

Conifer Holdings Reports 2024 Fourth Quarter and Year End Financial Results

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

TROY, Mich., March 28, 2025 (GLOBE NEWSWIRE) — Conifer Holdings, Inc. (Nasdaq: CNFR) (“Conifer” or the “Company”) today announced results for the fourth quarter and year ended December 31, 2024. Year End 2024 Financial HighlightsNet income allocable to common shareholders of $23.5 million $61 Million gain on sale of insurance agency operations in August 2024 Continuing Personal Lines business profitable for the fourth quarter of 2024 Book value per share of $1.76 as of December 31, 2024Management Comments Brian Roney, CEO of Conifer, commented, “2024 was indeed a transitional year for Conifer Holdings as we successfully sold our insurance agency operations, paid down considerable debt, further strengthened reserves, streamlined our organization overall, and focused our production efforts on select personal lines going forward.” Reduction...

HCW Biologics Reports Fourth Quarter and Fiscal Year 2024 Business Highlights and Financial Results

Written by Customer Service on March 28, 2025. Posted in Earnings Releases And Operating Results.

MIRAMAR, Fla., March 28, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between inflammation and age-related diseases, today reported financial results and recent business highlights for its fourth quarter and fiscal year ended December 31, 2024. Dr. Hing Wong, Founder and CEO, stated, “We are more passionate than ever about our desire to create breakthrough immunotherapeutic treatments for diseases with no known cures, especially pancreatic, ovarian cancer and other age-related diseases. We have received clearance to begin clinical trials in alopecia areata, our first-quality-of-life indication, with one of our lead molecules, HCW9302....

RCP Small and Emerging Fund III, LP Closes on ~$170 Million

Written by Customer Service on March 28, 2025. Posted in Public Companies.

CHICAGO, March 28, 2025 (GLOBE NEWSWIRE) — RCP Advisors, a private equity investment firm that provides access to North American small buyout fund managers through primary funds, secondary funds, and co-investment funds, as well as customized solutions and research services, announced the final closing of RCP Small and Emerging Fund III, LP (“RCP SEF III” or the “Fund”). The Fund closed on approximately $170.3 million in capital commitments, exceeding its target fund size. The Fund has a broad LP base of new and existing investors, including family offices, insurance companies, and high-net-worth individuals. “We want to express our sincere gratitude to our limited partners for their continued faith and confidence in our team and strategy. Small company buyouts continue to provide compelling investment opportunities, and we are...

This Is a Test From GlobeNewswire

Written by Customer Service on March 28, 2025. Posted in Public Companies.

This is an Abstract BackgroundThis is a test from GlobeNewswire. Readers are advised to disregard. TESTING — TESTING — TESTING — TESTING — TESTING –-END- CONTACT: Karen Yu Director, GlobeNewswire Product Management +1 310 258 6917

Koryx Copper Completes Internal Restructure to Simplify Corporate and Reporting Structures

Written by Customer Service on March 28, 2025. Posted in Public Companies.

VANCOUVER, British Columbia, March 28, 2025 (GLOBE NEWSWIRE) — Koryx Copper Inc. (“Koryx” or the “Company”) (TSXV: KRY) is pleased to announce that it has completed a vertical short-form amalgamation (the “Amalgamation“) pursuant to the Business Corporations Act (British Columbia) (the “BCBCA“) effective March 19, 2025, with the Company’s wholly-owned subsidiary 1054137 B.C. Ltd. (“SubCo”) (a company incorporated under the British Columbia Corporations Act). On August 30, 2016, the Company completed a share exchange with the shareholders of SubCo, giving effect to the restructure transaction. (the “Transaction”). The effect of the Transaction is that all assets and liabilities of SubCo were consolidated within the Company and SubCo then became dormant within the reporting structure of the group. The purpose...

Treace Announces Clinical Study Data Demonstrating Positive Lapiplasty® and Adductoplasty® Outcomes at the 2025 ACFAS Annual Scientific Conference

Written by Customer Service on March 28, 2025. Posted in Public Companies.

PONTE VEDRA, Fla., March 28, 2025 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced the presentation of updated interim data for the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, as well as the first presentation of the MTA3D™ Adductoplasty® clinical study, at the 2025 American College of Foot and Ankle Surgeons (ACFAS) Annual Meeting in Phoenix, Arizona. “We are excited to feature our growing body of clinical data to surgeons attending the 2025 ACFAS conference,” stated John T. Treace, CEO, Founder and Board Member of Treace. “This builds on our commitment...

Sword Group : Notice of Convocation to the Shareholders for the Ordinary and Extraordinary General Meeting of the Company on April 28 2025

Written by Customer Service on March 28, 2025. Posted in Public Companies.

Ladies and Gentlemen shareholders are hereby notified that they are summoned to the Ordinary and Extraordinary General Meeting on April 28, 2025, at 11:00 am at the registered office to deliberate on the following agenda: Under the authority of the General Meeting acting under the quorum and majority conditions of an Ordinary General Meeting:– Reading of the management report of the Board of Directors, including the report on the management of the Group, and report on the conclusion of the agreements referred to in article L.441-7 of the amended law of 10 August 1915 relating to the financial year ended 31 December 2024;– Reading of the Statutory Auditor’s report on the 2024 financial statements, the Group’s consolidated financial statements and on the performance of his assignment;– Approval of the statutory...

Independent Bank Corporation Announces Date for Its First Quarter 2025 Earnings Release

Written by Customer Service on March 28, 2025. Posted in Public Companies.

GRAND RAPIDS, Mich., March 28, 2025 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP), the holding company of Independent Bank, a Michigan-based community bank, announced that it expects to issue its 2025 first quarter results on Thursday, April 24, 2025, at approximately 8:00 am ET. The release will be available on the Internet at IndependentBank.com within the “News” section of the “Investor Relations” area of the Company’s website. Brad Kessel, President and CEO, Gavin Mohr, CFO and Joel Rahn, EVP Commercial Banking will review the quarterly results in a conference call for investors and analysts beginning at 11:00 am ET on Thursday, April 24, 2025. To participate in the live conference call, please dial 1-833-470-1428 (Access Code # 706949). Also, the conference call will be accessible through an audio webcast...

Month: March 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals